CD274 and cancer: Apparently, PD-L1 expression plays a key role in poor prognosis and resistance after treatment in several types of cancers, thereby adding an anti-PD-1 or anti-PD-L1 therapy may improve the efficacy and become a promising therapeutic strategy.